Indeed A2A antagonists have been proposed to improve several non-motor symptoms such as excessive daytime sleepiness [67], cognition and depression [68], while NR2B antagonists could improve depression and anxiety [69]. Here, IGKV2D-29 is linked to depressive symptom measurement.